PALISADE BIO, INC.
PALI evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $359.0M
- Lead Asset:
- pali-2108 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for PALI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PALI
Palisade Bio, Inc. (PALI) is a clinical-stage biopharmaceutical company developing PALI-2108, a PDE4 inhibitor for ulcerative colitis and Crohn's disease, with cash of $125.2M as of 2026-06-30 [sec].
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$359.0M
Cash Runway
—
Lead Asset
pali-2108 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials for PALISADE BIO, INC..
Palisade Bio, Inc. (PALI) is a clinical-stage biopharmaceutical company developing PALI-2108, a PDE4 inhibitor for ulcerative colitis and Crohn's disease, with cash of $125.2M as of 2026-06-30 [sec].
- Clinical-stage biopharmaceutical company developing next-generation therapies for inflammatory bowel diseases [sec_mda · as of 2026-03-20].
- Lead drug candidate PALI-2108 is a once-daily oral PDE4 inhibitor advancing into Phase II for ulcerative colitis and Crohn's disease [news · published 2026-09-27].
- Cash and cash equivalents of $125.2 million as of June 30, 2026 [sec].
- Net loss of -$10.6 million for the six months ended June 30, 2026 [sec].
- Japanese patent granted covering composition of matter for PALI-2108 in December 2025 [news · published 2025-12-30].
What works
- Cash runway through major clinical milestones: $125.2M as of June 30, 2026 is expected to fund operations through primary efficacy readouts in Phase 2 trials for UC (H2 2027) and CD (early 2028) [sec_mda · as of 2026-08-10].
- Lead candidate PALI-2108 is described as the first and only PDE4 inhibitor in development targeting the terminal ileum and colon for UC and fibrostenotic Crohn's disease, addressing significant unmet medical needs [news · published 2025-12-30].
- Company has no significant contractual obligations currently [sec_mda · as of 2026-08-10].
What to weigh
- Company has incurred significant operating losses and negative cash flows since inception and has not generated significant revenues or achieved operating profitability [sec_mda · as of 2026-08-10].
- Net loss of -$10.6 million for the six months ended June 30, 2026 [sec].
- Future capital requirements depend on many factors and additional funding will be needed for future clinical activities; no assurance of success in obtaining financing on acceptable terms [sec_mda · as of 2026-03-20].
From the filings
Quoted directly from source documents.
PALI-2108 is a once-daily oral PDE4 inhibitor advancing into Phase II
“Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program.”
News · September 27, 2026
Cash runway through Phase 2 readouts
“Based upon our cash and cash equivalents balance of $125.2 million as of June 30, 2026, we believe we have sufficient capital to fund our operations through major clinical development milestones including a primary efficacy readout of our Phase 2 ASCENTRA-UC clinical trial that is expected in the second half of 2027 and a primary efficacy readout of our planned ASCENTRA-CD clinical trial that is expected in early 2028.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2026-08-28 · Phase 2 start for PALI-2108 (ASCENTRA-UC and ASCENTRA-CD) — Phase 2 multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of PALI-2108.
Risks & what to watch (3)›
Key risks
- No revenue, ongoing losses — Company has not generated significant revenues nor achieved profitability; net loss of -$10.6M in H1 2026 [sec].
- Future funding uncertainty — Additional funding required for future clinical activities; no assurance of success in obtaining financing [sec_mda · as of 2026-03-20].
- Clinical trial risk — Phase 2 trials for UC and CD are ongoing; efficacy and safety outcomes are uncertain [sec_mda · as of 2026-08-10].
What to watch
- Primary efficacy readout of Phase 2 ASCENTRA-UC trial expected in H2 2027 [sec_mda · as of 2026-08-10].
- Primary efficacy readout of Phase 2 ASCENTRA-CD trial expected in early 2028 [sec_mda · as of 2026-08-10].
- Cash burn rate and any changes in operating plan that may affect runway [sec_mda · as of 2026-08-10].
Sources: Catalysts · News · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run PALISADE BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALISADE BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
6 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 15.6%
- Days to cover
- 5.2
- Shares short
- 26,147,446
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PALI short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALISADE BIO, INC.?
Palisade Bio, Inc. (PALI) is a clinical-stage biopharmaceutical company developing PALI-2108, a PDE4 inhibitor for ulcerative colitis and Crohn's disease, with cash of $125.2M as of 2026-06-30 [sec].
What is PALISADE BIO, INC.'s lead drug candidate?
PALISADE BIO, INC.'s most advanced tracked candidate is pali-2108 (Phase 2) for Ulcerative Colitis (UC); Fibrostenotic Crohn's Disease.
Who is the CEO of PALISADE BIO, INC.?
Mr. J. D. Finley is the chief executive officer of PALISADE BIO, INC. (PALI).
Where is PALISADE BIO, INC. headquartered?
PALISADE BIO, INC. (PALI) is headquartered in Denver, CO, United States.
What therapeutic areas does PALISADE BIO, INC. focus on?
PALISADE BIO, INC. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.